text: <unk>  is a kinase inhibitor that is FDA approved for the treatment of adult patients with:
  Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.
  Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include diarrhea or colitis, neutropenia, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, and anemia.
option_0: Duvelisib
option_1: Glasdegib
option_2: Alpelisib
option_3: Idelalisib
option_4: Vismodegib
option_5: Atosiban
option_6: Phenkapton
option_7: Sdasdfadfasf